mathias1981
New Member
- Reaction score
- 0
Here is the link to the whole article:
http://phx.corporate-ir.net/phoenix.zht ... id=833989&
Good but not yet exciting news...
Curis Reaches First Preclinical Milestone in Hair Growth Program with Procter & Gamble
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 21, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that it has reached the first preclinical milestone in a hair growth program with Procter & Gamble Pharmaceuticals, a division of The Procter & Gamble Company (NYSE: PG). The program is focused upon the potential development of a topical Hedgehog agonist for hair growth disorders, such as male pattern baldness and female pattern hair loss. As part of the initial agreement signed in September of 2005, P&G agreed to pay Curis up to $2.8 million in preclinical milestones. The first of two preclinical milestones has now been successfully completed.
"This first preclinical milestone represents the successful completion of several initial steps toward our goal of bringing a topical Hedgehog agonist into the clinic for the treatment of hair growth disorders," said Daniel R. Passeri, President and Chief Executive Officer of Curis, Inc. "We are pleased by the progress that the joint research team has made, particularly since our collaboration with Procter & Gamble began only five months ago. We are hopeful that this will be the first of several development achievements that will allow Curis and Procter & Gamble to advance a Hedgehog agonist into clinical development and ultimately succeed in providing an effective treatment for hair growth disorders. Under our collaboration with P&G, Curis has retained an option to co-develop this product from IND filing through Phase II trials. We believe that this co-development structure provides an opportunity for Curis to create additional value for our shareholders."
About the Procter & Gamble Curis Collaboration
In September 2005, Curis and Procter & Gamble entered into a research and development agreement to evaluate and develop potential treatments for hair growth disorders utilizing Curis' Hedgehog agonist technology. Future efforts may be expanded to address other skin disorders.
Under the terms of the agreement, Curis has granted P&G an exclusive, worldwide royalty-bearing license for the non-systemic, dermatological use of Curis' Hedgehog agonist technology, via topical administration. Curis will have an option to co-develop a development candidate through Phase II clinical trials, should an investigational new drug application be filed with the FDA. Curis has retained rights to certain non-systemic applications of the Hedgehog agonist technology, specifically for local cardiovascular and ex vivo use. Curis has also retained rights to veterinary applications of the technology, to which P&G has the first option to negotiate a commercial arrangement.
http://phx.corporate-ir.net/phoenix.zht ... id=833989&
Good but not yet exciting news...
Curis Reaches First Preclinical Milestone in Hair Growth Program with Procter & Gamble
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 21, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that it has reached the first preclinical milestone in a hair growth program with Procter & Gamble Pharmaceuticals, a division of The Procter & Gamble Company (NYSE: PG). The program is focused upon the potential development of a topical Hedgehog agonist for hair growth disorders, such as male pattern baldness and female pattern hair loss. As part of the initial agreement signed in September of 2005, P&G agreed to pay Curis up to $2.8 million in preclinical milestones. The first of two preclinical milestones has now been successfully completed.
"This first preclinical milestone represents the successful completion of several initial steps toward our goal of bringing a topical Hedgehog agonist into the clinic for the treatment of hair growth disorders," said Daniel R. Passeri, President and Chief Executive Officer of Curis, Inc. "We are pleased by the progress that the joint research team has made, particularly since our collaboration with Procter & Gamble began only five months ago. We are hopeful that this will be the first of several development achievements that will allow Curis and Procter & Gamble to advance a Hedgehog agonist into clinical development and ultimately succeed in providing an effective treatment for hair growth disorders. Under our collaboration with P&G, Curis has retained an option to co-develop this product from IND filing through Phase II trials. We believe that this co-development structure provides an opportunity for Curis to create additional value for our shareholders."
About the Procter & Gamble Curis Collaboration
In September 2005, Curis and Procter & Gamble entered into a research and development agreement to evaluate and develop potential treatments for hair growth disorders utilizing Curis' Hedgehog agonist technology. Future efforts may be expanded to address other skin disorders.
Under the terms of the agreement, Curis has granted P&G an exclusive, worldwide royalty-bearing license for the non-systemic, dermatological use of Curis' Hedgehog agonist technology, via topical administration. Curis will have an option to co-develop a development candidate through Phase II clinical trials, should an investigational new drug application be filed with the FDA. Curis has retained rights to certain non-systemic applications of the Hedgehog agonist technology, specifically for local cardiovascular and ex vivo use. Curis has also retained rights to veterinary applications of the technology, to which P&G has the first option to negotiate a commercial arrangement.
